Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and ...
SUDO-550, an oral therapy for MS, was found to be safe and to reach the brain in its first human clinical trial, trial ...
News-Medical.Net on MSN
Preclinical evidence supports sotagliflozin's superior efficacy in attenuating salt-induced kidney damage
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback